{
  "docId": "019dd923-5e88-73ef-bd5a-9cdc5d048fe2",
  "docSlug": "03e126adc7ca1480",
  "documentTitle": "20250114 bayer handout jpm 2025",
  "authorId": "JPMorgan",
  "authorName": "Bayer",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 16,
  "pageCount": 18,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "LoE stands for Loss of Exclusivity.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "photo"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-9cdc5d048fe2/16",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.68,
        "w": 0.3,
        "x": 0.65,
        "y": 0.23
      },
      "kind": "image",
      "text": "BAYER PHARMA. Treat the untreatable. Cure disease. Offer hope.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c817697b-a1ea-41d0-aa83-53375abf66b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.55,
        "x": 0.08,
        "y": 0.66
      },
      "kind": "list",
      "text": "Rapid rebuild of competitive pipeline is in full swing, based on new Innovation Model",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cb44fb5-fa53-48e2-9737-a944d59ba09a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.55,
        "x": 0.08,
        "y": 0.8
      },
      "kind": "list",
      "text": "New Operating Model is driving productivity and efficiency gains amid LoE pressures and growth investments",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e0e2474-8c36-4882-b342-056d208f1cab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.55,
        "x": 0.08,
        "y": 0.52
      },
      "kind": "list",
      "text": "Upcoming launches of Acoramidis and Elinzanetant to drive further growth momentum",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7df474d5-d968-4175-ab25-d8c997eb2205",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.55,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "list",
      "text": "Three strategic priorities: Renew topline – grow pipeline value – leverage new operating model",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec6e21a1-c611-4255-aeec-fbb80e32b8c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.55,
        "x": 0.08,
        "y": 0.38
      },
      "kind": "list",
      "text": "Successful launches of Nubeqa, Kerendia and Eylea 8mg to largely balance LoEs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc7d29c7-27a1-44ca-befe-7eda910874d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.08,
        "y": 0.05
      },
      "kind": "title",
      "text": "Building Momentum for Long-term Growth as of 2027 while Managing LoE Transition",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f57db301-3d77-42b5-a957-f752f2e6c810",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "b3322952-358a-47df-b632-fcefa9721754",
      "evidence": "title/headline: Building Momentum for Long-term Growth as of 2027 while Managing LoE Transition",
      "confidence": 0.5
    },
    {
      "name": "Three Pillars",
      "slug": "three-pillars",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "b0ac9fd3-2864-4aac-9aff-a2fbc250765e",
      "evidence": "Three strategic priorities: Renew topline – grow pipeline value – leverage new operating model",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 15,
      "beatId": "335d567b-6530-47e5-af7a-b7d5b8ce502b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The final slides outline the company's plans for growth and profitability",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}